Ivashchuk Yu. V

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Recent years have shown that patients with rheumatoid arthritis (RA) have a higher risk of cardiovascular complications and mortality. Rheumatoid arthritis is a common and severe chronic inflammatory joint disease, the frequency of which in the population ranges from 0.5 to 1.0%. It is one of the most widespread autoimmune diseases in the world leading to early disability, and therefore the need to improve the approaches to clinical management of such patients is obvious. The most common comorbid conditions among RA patients are hypertension (HT). At present, it remains an open-ended question to study the diagnosis of comorbid cardiovascular conditions in patients with rheumatoid arthritis for the purpose of drug correction of dyslipidemia. The aim of the study. To determine the peculiarities of diurnal profile of AP, blood lipid spectrum in patients with HT in combination with RA and to evaluate the effectiveness of using average doses of rosuvastatin to correct dyslipidemia in this group of patients. Results. Changes in indicators of the diurnal artery pressure profile, detected in most patients with hypertension in combination with rheumatoid arthritis, were characterized by increased average daytime, average night time levels of systolic AP, increased daytime variability and a lower degree of nocturnal decrease in comparison with patients without RA. Most of the patients examined had increased triglycerides, low-density lipoprotein cholesterol, total cholesterol – 17 (40.48%), 24 (57.14%) and 21 (50%) patients, respectively, and 18 (42,86%) patients had decreased high-density lipoprotein cholesterol. The use of 20 mg of rosuvastatin as part of complex therapy in patients with HT in combination with RA contributed to the achievement of target indicator levels of lipid spectrum in blood of most patients.

hypertension, rheumatoid arthritis, circadian blood pressure profile, blood lipid profile, rosuvastatin, lipoproteins, circadian blood pressure profile.

1. Rekomendatsiyi z likuvannya arterialnoyi gipertoniyi. ESH ESC 2017. Pereklad RKO. Kardiologichniy zhurnal. 2017;1(105):7-94. [in Ukrainian].
2. Voloshina OB, Udovitsya VO, Lisiy IS, Dukova OR, Chayka AO, Dichko TO. Sposib diferentsiynoyi diagnostiki psevdorezistentnoyi arterialnoyi gipertenziyi vid rezistentnoyi arterialnoyi gipertenziyi. Odeskiy natsionalniy medichniy universitet. 2017. s. 19. [in Ukrainian].
3. Popkova TV, Novikova DS, Nasonov EL. Kardiovaskulyarnyie faktoryi riska pri revmaticheskih zabolevaniyah: svyaz s vospaleniem. Consilium Medicum. 2017;2:112-8. [in Russian].
4. García-González A, Gaxiola-Robles R, Zenteno-Savín T. Oxidative stress in patients with rheumatoid arthritis. Rev Invest Clin. 2015;67:46-53.
5. Ambrosino P, Lupoli R, Minno AD, Tasso M, Peluso R, Dario Di Minno MN. Subclinical atherosclerosis in patients with rheumatoid arthritis. Thromb Haemost. 2015;113:916-30.
6. Zhang J, Chen L, Delzell E, Muntner P, Hillegass WB, Safford MM, et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014 Jul;73(7):1301-8.
7. Nowak WN, Deng J, Ruan XZ, Xu Q. Reactive oxygen species generation and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2017;37(5):41-52.
8. Obertinska OG. Rezistentna arterialna gipertenziya: poshuk optimalnoyi kombinovanoyi terapiyi. Ukrayinskiy kardiologichniy zhurnal. 2017;6:113-23. [in Ukrainian].
9. Protsenko GA. Paraneoplastichni sindromi v revmatologichniy praktitsi. Ukr. revmatol. zhurn. 2016;63:29. [in Ukrainian].
10. European Society of Hypertension European Society of Cardiology guidelines for the manage ment of arterial hypertension. J. Hypertens. 2013;31(7):1281-357.
11. Aleksandrov AV, Grekhov RA, Shilova LN, Alohіna IYu. Novі mozhlivostі polіpshennya yakostі rann’oі dіagnostiki revmatologіchnih zahvoryuvan’. 2017;11(2):255-8. [in Ukrainian].
12. Turdialieva SA, Mozharovskaya EA, Kudrina OM, Cherkashin DV. Naibolee chasto vstrechayushchiesya zabolevaniya sustavov: aktual’nye voprosy diagnostiki i lecheniya. Vestn. Ros. voen.-med. akad. 2017;3:227-33. [in Russian].
13. Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 2014 Mar;73(3):609-15.

«Bulletin of problems biology and medicine» Issue 2 (156), 2020 year, 103-107 pages, index UDK 616.12-008.331.1+616.72-002.77:616.13-0046]-08

10.29254/2077-4214-2020-2-156-103-107